Livers

DMG-PEG1000-Galactose is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and terminal galactose. DMG-PEG1000-Galactose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of galactose, making it suitable for research in biomaterial construction and drug delivery.

DMG-PEG3400-Galactose is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and terminal galactose. DMG-PEG3400-Galactose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of galactose, making it suitable for research in biomaterial construction and drug delivery.

DMG-PEG2000-Galactose is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and terminal galactose. DMG-PEG2000-Galactose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of galactose, making it suitable for research in biomaterial construction and drug delivery.

DMG-PEG10000-Galactose is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and terminal galactose. DMG-PEG10000-Galactose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of galactose, making it suitable for research in biomaterial construction and drug delivery.

DSPE-PEG3400-pPB is a PEG compound which composed of DSPE and a cyclic oligopeptide (pPB). pPB has a strong binding affinity with PDGFRβ, which is overexpressed on activated hepatic stellate cells (HSC). DSPE-PEG3400-pPB can be used for drug delivery.

DSPE-PEG2000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG2000-VIP can be used for drug delivery.

DSPE-PEG3400-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG3400-VIP can be used for drug delivery.

DSPE-PEG1000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG1000-R9 can be used for drug delivery.

DSPE-PEG3400-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG3400-R9 can be used for drug delivery.

DSPE-PEG1000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG1000-VIP can be used for drug delivery.

DSPE-PEG5000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG5000-R9 can be used for drug delivery.

DSPE-PEG5000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG5000-VIP can be used for drug delivery.

DSPE-PEG5000-pPB is a PEG compound which composed of DSPE and a cyclic oligopeptide (pPB). pPB has a strong binding affinity with PDGFRβ, which is overexpressed on activated hepatic stellate cells (HSC). DSPE-PEG5000-pPB can be used for drug delivery.

Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3⁺CD8⁺ central and CD3⁺CD8⁺ effector memory T cells and decrease the percentage of CD3⁺ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model.

Lipid 119-23 is an ionizable cationic lipid which can be utilized in the formation of lipid nanoparticles and the delivery of mRNA. Lipid 119-23 exhibits an enhanced capability to express functional mCre in several categories of immune cells, spanning the liver, spleen and lung.

Am-Ka12K4 is a weakly positively charged peptide-based ionizable lipid. Am-Ka12K4 induces membrane disruption under endosomal pH conditions and possesses high lipid fusion capacity. Am-Ka12K4 forms tightly packed, stable lipid nanoparticles. Am-Ka12K4 mediates in vivo mRNA delivery, exhibits inherent liver tropism, and can be modified to adjust organ tropism, enabling selective mRNA delivery to the spleen, lung, or thymus. Am-Ka12K4 is applicable to research related to repetitive mild traumatic brain injury.

a12Dab4 is a peptide ionizable lipid (PIL) used in lipid nanoparticle (LNP) formulations for targeted delivery of mRNA to the liver.